19 OpenTox Principles and Best Practices for Trusted Reproducible …
403
was appointed Chief Scientific Officer (CSO). Main research areas he is coordinating are data and
knowledge management, integrating testing strategies combining alternative in vitro and in silico
methods for predictive toxicology and risk assessment as well as approaches to foster collaborative research and community activities. He is Author and Co-Author of more than 50 articles in
peer-reviewed international journals and several other scientific contributions.
Connor Hardy is Web Publisher and Technical Assistant at Douglas Connect. He is an experienced Web Designer with a demonstrated history. He has experience in Search Engine Optimization (SEO), Corporate Website Management, Client/Product Service, Publication Strategy, Video
Editing/Production, and Community Web Project Management. He graduated from Mercyhurst
University.
Weida Tong is Director of Division of Bioinformatics and Biostatistics at FDA’s National Center for Toxicological Research (NCTR/FDA). He has served as Science Advisory Board Member for several large projects involving multiple institutes in Europe and the USA. He also holds
several adjunct positions at universities in the USA and China. His division at FDA works to
develop bioinformatic methodologies and standards to support FDA research and regulation and to
advance regulatory science and personalized medicine. The most visible projects from his group
are (1) leading the microarray quality control (MAQC) consortium to develop standard analysis
protocols and quality control metrics for emerging technologies to support regulatory science and
precision medicine; (2) development of liver toxicity knowledge base (LTKB) for drug safety; (3)
in silico drug repositioning for the enhanced treatment of rare diseases; and (4) development of the
FDA bioinformatics system, ArrayTrackTM suite, to support FDA review and research on pharmacogenomics. In addition, his group also specializes in molecular modeling and QSARs with a
specific interest in estrogen, androgen, and endocrine disruptor. He has published more than 230
papers and chapters.
Daniel Burgwinkel is an expert in blockchain technology located in Basel, Switzerland, and currently working for Guardtime. He is an experienced Advisor and Program Manager with a demonstrated history of working in the pharmaceuticals industry, financial services, and e-government.
He is skilled in blockchain technology, information governance, record management, and business
process management. He is a strong entrepreneurship professional with a Doctor of Philosophy
(Ph.D.) from University of St. Gallen and a Masters in Business Engineering.
Richard Bergström is External Pharma Lead, SICPA SA. He previously was Director General
of the European Federation of Pharmaceutical Industries and Associations (EFPIA) from April
2011 to 2016. He served for nine years as Director General of LIF, the Swedish Association of
the Pharmaceutical Industry, following positions in Switzerland in regulatory affairs at the pharmaceutical companies Roche and Novartis. He was also appointed by the Swedish Government
to the Board of the Karolinska Institutet. He is Pharmacist by training, receiving his MScPharm
from the University of Uppsala, Sweden in 1988.
403
was appointed Chief Scientific Officer (CSO). Main research areas he is coordinating are data and
knowledge management, integrating testing strategies combining alternative in vitro and in silico
methods for predictive toxicology and risk assessment as well as approaches to foster collaborative research and community activities. He is Author and Co-Author of more than 50 articles in
peer-reviewed international journals and several other scientific contributions.
Connor Hardy is Web Publisher and Technical Assistant at Douglas Connect. He is an experienced Web Designer with a demonstrated history. He has experience in Search Engine Optimization (SEO), Corporate Website Management, Client/Product Service, Publication Strategy, Video
Editing/Production, and Community Web Project Management. He graduated from Mercyhurst
University.
Weida Tong is Director of Division of Bioinformatics and Biostatistics at FDA’s National Center for Toxicological Research (NCTR/FDA). He has served as Science Advisory Board Member for several large projects involving multiple institutes in Europe and the USA. He also holds
several adjunct positions at universities in the USA and China. His division at FDA works to
develop bioinformatic methodologies and standards to support FDA research and regulation and to
advance regulatory science and personalized medicine. The most visible projects from his group
are (1) leading the microarray quality control (MAQC) consortium to develop standard analysis
protocols and quality control metrics for emerging technologies to support regulatory science and
precision medicine; (2) development of liver toxicity knowledge base (LTKB) for drug safety; (3)
in silico drug repositioning for the enhanced treatment of rare diseases; and (4) development of the
FDA bioinformatics system, ArrayTrackTM suite, to support FDA review and research on pharmacogenomics. In addition, his group also specializes in molecular modeling and QSARs with a
specific interest in estrogen, androgen, and endocrine disruptor. He has published more than 230
papers and chapters.
Daniel Burgwinkel is an expert in blockchain technology located in Basel, Switzerland, and currently working for Guardtime. He is an experienced Advisor and Program Manager with a demonstrated history of working in the pharmaceuticals industry, financial services, and e-government.
He is skilled in blockchain technology, information governance, record management, and business
process management. He is a strong entrepreneurship professional with a Doctor of Philosophy
(Ph.D.) from University of St. Gallen and a Masters in Business Engineering.
Richard Bergström is External Pharma Lead, SICPA SA. He previously was Director General
of the European Federation of Pharmaceutical Industries and Associations (EFPIA) from April
2011 to 2016. He served for nine years as Director General of LIF, the Swedish Association of
the Pharmaceutical Industry, following positions in Switzerland in regulatory affairs at the pharmaceutical companies Roche and Novartis. He was also appointed by the Swedish Government
to the Board of the Karolinska Institutet. He is Pharmacist by training, receiving his MScPharm
from the University of Uppsala, Sweden in 1988.